nach oben

World Journal of Surgery

Erschienen in:

01.12.2011

Candida Peritonitis: An Update on the Latest Research and Treatments

verfasst von: Herman Anthony Carneiro, Anastasios Mavrakis, Eleftherios Mylonakis

Erschienen in: World Journal of Surgery | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

British Society for Antimicrobial Chemotherapy Working Party (1994) Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 20:522–528

Edwards JE Jr., Bodey GP, Bowden RA et al (1997) International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 25:43–59PubMed

Eggimann P, Calandra T, Fluckiger U et al (2005) Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. Intensive Care Med 31:1514–1521PubMed

Falagas ME, Apostolou KE, Pappas VD (2006) Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 25:419–425PubMed

Wenzel RP, Gennings C (2005) Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 41(Suppl 6):S389–S393PubMed

Viscoli C, Girmenia C, Marinus A et al (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28:1071–1079PubMed

Bassetti M, Righi E, Costa A et al (2006) Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6:21PubMed

Blot SI, Vandewoude KH, De Waele JJ (2007) Candida peritonitis. Curr Opin Crit Care 13:195–199PubMed

Blot S, Vandewoude K (2004) Management of invasive candidiasis in critically ill patients. Drugs 64:2159–2175PubMed

10.

Blot S, De Waele JJ (2005) Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 65:1611–1620PubMed

11.

Mean M, Marchetti O, Calandra T (2008) Bench-to-bedside review: candida infections in the intensive care unit. Critical Care (Lond) 12:204

12.

Sawyer RG, Adams RB, Rosenlof LK et al (1995) The role of Candida albicans in the pathogenesis of experimental fungal/bacterial peritonitis and abscess formation. Am Surg 61:726–731PubMed

13.

Roehrborn A, Thomas L, Potreck O et al (2001) The microbiology of postoperative peritonitis. Clin Infect Dis 33:1513–1519PubMed

14.

Dupont H, Bourichon A, Paugam-Burtz C et al (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Critical Care Med 31:752–757

15.

Rex JH (2006) Candida in the peritoneum: passenger or pathogen? Crit Care Med 34:902–903PubMed

16.

Sotto A, Lefrant JY, Fabbro-Peray P et al (2002) Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 50:569–576PubMed

17.

de Ruiter J, Weel J, Manusama E et al (2009) The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection 37:522–527PubMed

18.

Petri MG, Konig J, Moecke HP et al (1997) Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich society for chemotherapy, divisions of mycology and pneumonia research. Intensive Care Med 23:317–325PubMed

19.

Matuszkiewicz-Rowinska J (2009) Update on fungal peritonitis and its treatment. Perit Dial Int 29(Suppl 2):S161–S165PubMed

20.

Gullo A (2009) Invasive fungal infections: the challenge continues. Drugs 69(Suppl 1):65–73PubMed

21.

Leroy O, Gangneux JP, Montravers P et al (2009) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 37:1612–1618PubMed

22.

Wang DH, Gao XJ, Wei LQ et al (2009) The preemptive treatment of invasive Candida infection with reference of corrected colonization index in critically ill patients: a multicenter, prospective, randomized controlled clinical study [in Chinese]. Chinese Crit Care Med 21:525–528

23.

Islam S, Zaidi AK, Wilson J (2002) Peritoneal infection with multiple species of Candida: a case report. Surg Infect 3:35–37

24.

Shan YS, Hsu HP, Hsieh YH et al (2003) Significance of intraoperative peritoneal culture of fungus in perforated peptic ulcer. Br J Surg 90:1215–1219PubMed

25.

Montravers P, Dupont H, Gauzit R et al (2006) Candida as a risk factor for mortality in peritonitis. Critical Care Med 34:646–652

26.

Solomkin JS, Flohr AB, Quie PG et al (1980) The role of Candida in intraperitoneal infections. Surgery 88:524–530PubMed

27.

Calandra T, Bille J, Schneider R et al (1989) Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 2:1437–1440PubMed

28.

Yang C, Yeh CT, Hung CF et al (1999) Case report: spontaneous peritonitis caused by Candida albicans. J Gastroenterol Hepatol 14:1041–1044PubMed

29.

Nathens AB, Rotstein OD, Marshall JC (1998) Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 22:158–163. doi:10.1007/s002689900364 PubMed

30.

Rotstein OD, Pruett TL, Simmons RL (1986) Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit. Can J Surg 29:247–250PubMed

31.

Sawyer RG, Rosenlof LK, Adams RB et al (1992) Peritonitis into the 1990s: changing pathogens and changing strategies in the critically ill. Am Surg 58:82–87PubMed

32.

Sandven P, Qvist H, Skovlund E et al (2002) Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 30:541–547PubMed

33.

Khan ZU, Mustafa AS (2001) Detection of Candida species by polymerase chain reaction (PCR) in blood samples of experimentally infected mice and patients with suspected candidemia. Microbiol Res 156:95–102PubMed

34.

Schulze J, Sonnenborn U (2009) Yeasts in the gut: from commensals to infectious agents. Deutsches Arzteblatt Int 106:837–842

35.

Johnson DW, Cobb JP (2010) Candida infection and colonization in critically ill surgical patients. Virulence 1:355–356PubMed

36.

Pittet D, Monod M, Suter PM et al (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751–758PubMed

37.

Dupont H, Paugam-Burtz C, Muller-Serieys C et al (2002) Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg 137:1341–1346; discussion 1347PubMed

38.

Lee SC, Fung CP, Chen HY et al (2002) Candida peritonitis due to peptic ulcer perforation: incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B. Diagn Microbiol Infect Dis 44:23–27PubMed

39.

Diebel LN, Liberati DM, Diglio CA et al (1999) Synergistic effects of Candida and Escherichia coli on gut barrier function. J Trauma 47:1045–1050; discussion 1050–1041PubMed

40.

Diebel LN, Liberati DM, Dulchavsky SA et al (1997) An in vitro model to assess mucosal immune function and bacterial translocation. J Surg Res 69:178–182PubMed

41.

Kilian M, Reinholdt J, Lomholt H et al (1996) Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. APMIS 104:321–338PubMed

42.

Spanakis EK, Kourkoumpetis TK, Livanis G et al (2010) Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery. Mayo Clinic Proc 85:1073–1079

43.

Kourkoumpetis T, Manolakaki D, Velmahos G et al (2010) Candida infection and colonization among non-trauma emergency surgery patients. Virulence 1:359–366PubMed

44.

Manolakaki D, Velmahos G, Kourkoumpetis T et al (2010) Candida infection and colonization among trauma patients. Virulence 1:367–375PubMed

45.

Viale P (2009) Candida colonization and candiduria in critically ill patients in the intensive care unit. Drugs 69(Suppl 1):51–57PubMed

46.

Peleg AY, Hogan DA, Mylonakis E (2010) Medically important bacterial-fungal interactions. Nat Rev Microbiol 8:340–349PubMed

47.

Peleg AY, Tampakakis E, Fuchs BB et al (2008) Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. Proc Natl Acad Sci USA 105:14585–14590PubMed

48.

Burd RS, Raymond CS, Dunn DL (1992) Endotoxin promotes synergistic lethality during concurrent Escherichia coli and Candida albicans infection. J Surg Res 52:537–542PubMed

49.

Ikeda T, Suegara N, Abe S et al (1999) Efficacy of antibacterial drugs in mice with complex infection by Candida albicans and Escherichia coli. J Antibiot (Tokyo) 52:552–558

50.

Neely AN, Law EJ, Holder IA (1986) Increased susceptibility to lethal Candida infections in burned mice preinfected with Pseudomonas aeruginosa or pretreated with proteolytic enzymes. Infect Immun 52:200–204PubMed

51.

Roux D, Gaudry S, Dreyfuss D et al (2009) Candida albicans impairs macrophage function and facilitates Pseudomonas aeruginosa pneumonia in rat. Critical Care Med 37:1062–1067

52.

Wang Y, Xu XL (2008) Bacterial peptidoglycan-derived molecules activate Candida albicans hyphal growth. Commun Integr Biol 1:137–139PubMed

53.

Xu XL, Lee RT, Fang HM et al (2008) Bacterial peptidoglycan triggers Candida albicans hyphal growth by directly activating the adenylyl cyclase Cyr1p. Cell Host Microbe 4:28–39PubMed

54.

Akagawa G, Abe S, Yamaguchi H (1995) Mortality of Candida albicans-infected mice is facilitated by superinfection of Escherichia coli or administration of its lipopolysaccharide. J Infect Dis 171:1539–1544PubMed

55.

Klaerner HG, Uknis ME, Acton RD et al (1997) Candida albicans and Escherichia coli are synergistic pathogens during experimental microbial peritonitis. J Surg Res 70:161–165PubMed

56.

Gale D, Sandoval B (1957) Response of mice to the inoculations of both Candida albicans and Escherichia coli. I. The enhancement phenomenon. J Bacteriol 73:616–624PubMed

57.

Sawyer RG, Adams RB, May AK et al (1995) Development of Candida albicans and C. albicans/Escherichia coli/Bacteroides fragilis intraperitoneal abscess models with demonstration of fungus-induced bacterial translocation. J Med Vet Mycol 33:49–52PubMed

58.

Carlson E (1982) Synergistic effect of Candida albicans and Staphylococcus aureus on mouse mortality. Infect Immun 38:921–924PubMed

59.

Carlson E (1983) Enhancement by Candida albicans of Staphylococcus aureus, Serratia marcescens, and Streptococcus faecalis in the establishment of infection in mice. Infect Immun 39:193–197PubMed

60.

Carlson E, Johnson G (1985) Protection by Candida albicans of Staphylococcus aureus in the establishment of dual infection in mice. Infect Immun 50:655–659PubMed

61.

Onderdonk AB, Bartlett JG, Louie T et al (1976) Microbial synergy in experimental intra-abdominal abscess. Infect Immun 13:22–26PubMed

62.

Rotstein OD, Kao J, Houston K (1989) Reciprocal synergy between Escherichia coli and Bacteroides fragilis in an intra-abdominal infection model. J Med Microbiol 29:269–276PubMed

63.

Rotstein OD, Pruett TL, Simmons RL (1985) Lethal microbial synergism in intra-abdominal infections Escherichia coli and Bacteroides fragilis. Arch Surg 120:146–151PubMed

64.

Tampakakis E, Peleg AY, Mylonakis E (2009) Interaction of Candida albicans with an intestinal pathogen, Salmonella enterica serovar Typhimurium. Eukaryot Cell 8:732–737PubMed

65.

Hogan DA, Kolter R (2002) Pseudomonas–Candida interactions: an ecological role for virulence factors. Science 296:2229–2232PubMed

66.

Kruppa M (2009) Quorum sensing and Candida albicans. Mycoses 52:1–10PubMed

67.

De Sordi L, Muhlschlegel FA (2009) Quorum sensing and fungal-bacterial interactions in Candida albicans: a communicative network regulating microbial coexistence and virulence. FEMS Yeast Res 9:990–999PubMed

68.

Azoulay E, Timsit JF, Tafflet M et al (2006) Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 129:110–117PubMed

69.

Groll AH, Shah PM, Mentzel C et al (1996) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33:23–32PubMed

70.

Whicher J, Bienvenu J, Monneret G (2001) Procalcitonin as an acute phase marker. Ann Clin Biochem 38:483–493PubMed

71.

Jemli B, Aouni Z, Lebben I et al (2007) Procalcitonin in invasive candidosis. Ann Biol Clin (Paris) 65:169–173

72.

Charles PE, Castro C, Ruiz-Santana S et al (2009) Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis? Intensive Care Med 35:2146–2150PubMed

73.

Fisgin NT, Aliyazicioglu Y, Tanyel E et al (2010) The value of neopterin and procalcitonin in patients with sepsis. South Med J 103:216–219

74.

Kedzierska A, Kochan P, Pietrzyk A et al (2007) Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1 → 3)-beta-d-glucan antigens. Eur J Clin Microbiol Infect Dis 26:755–766PubMed

75.

Bayer AS, Blumenkrantz MJ, Montgomerie JZ et al (1976) Candida peritonitis. Report of 22 cases and review of the english literature. Am J Med 61:832–840PubMed

76.

Fujita S (2008) Serologic diagnosis of fungal infections. Nippon Rinsho 66:2313–2318PubMed

77.

Alam FF, Mustafa AS, Khan ZU (2007) Comparative evaluation of (1, 3)-beta-d-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia. BMC Infect Dis 7:103PubMed

78.

Alexander BD (2002) Diagnosis of fungal infection: new technologies for the mycology laboratory. Transpl Infect Dis 4(Suppl 3):32–37PubMed

79.

Nichterlein T, Buchheidt D, Hein A et al (2003) Comparison of glucan detection and galactomannan enzyme immunoassay in gastrointestinal and systemic murine candidiasis. Diagn Microbiol Infect Dis 46:103–108PubMed

80.

Odabasi Z, Mattiuzzi G, Estey E et al (2004) Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39:199–205PubMed

81.

Ostrosky-Zeichner L, Alexander BD, Kett DH et al (2005) Multicenter clinical evaluation of the (1 → 3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654–659PubMed

82.

Khan Z, Mustafa AS, Alam FF (2009) Real-time light cycler polymerase chain reaction and melting temperature analysis for identification of clinically important Candida spp. J Microbiol Immunol Infect 42:290–295PubMed

83.

Lau A, Halliday C, Chen SC et al (2009) Comparison of whole blood, serum and plasma for early detection of candidemia by multiplex-tandem PCR. J Clin Microbiol 48:811–816PubMed

84.

Garaizar J, Brena S, Bikandi J et al (2006) Use of DNA microarray technology and gene expression profiles to investigate the pathogenesis, cell biology, antifungal susceptibility and diagnosis of Candida albicans. FEMS Yeast Res 6:987–998PubMed

85.

White PL, Perry MD, Barnes RA (2009) An update on the molecular diagnosis of invasive fungal disease. FEMS Microbiol Lett 296:1–10PubMed

86.

Ibelings MS, Maquelin K, Endtz HP et al (2005) Rapid identification of Candida spp. in peritonitis patients by Raman spectroscopy. Clin Microbiol Infect 11:353–358PubMed

87.

van Veen SQ, Claas EC, Kuijper EJ (2010) High-throughput identification of bacteria and yeast by matrix-assisted laser desorption ionization mass spectrometry (MALDI-TOF MS) in routine medical microbiology laboratory. J Clin Microbiol 48:900–907PubMed

88.

Marinach-Patrice C, Fekkar A, Atanasova R et al (2010) Rapid species diagnosis for invasive candidiasis using mass spectrometry. PLoS One 5:e8862PubMed

89.

Marinach-Patrice C, Lethuillier A, Marly A et al (2009) Use of mass spectrometry to identify clinical Fusarium isolates. Clin Microbiol Infect 15:634–642PubMed

90.

Boer WH, van Ampting JM, Vos P (2007) Successful treatment of eight episodes of Candida peritonitis without catheter removal using intracatheter administration of amphotericin. B Perit Dial Int 27:208–210

91.

Solomkin JS, Flohr A, Simmons RL (1982) Candida infections in surgical patients. Dose requirements and toxicity of amphotericin B. Ann Surg 195:177–185PubMed

92.

Aperis G, Mylonakis E (2006) Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 15:579–602PubMed

93.

Aperis G, Myriounis N, Spanakis EK et al (2006) Developments in the treatment of candidiasis: more choices and new challenges. Expert Opin Investig Drugs 15:1319–1336PubMed

94.

Pappas PG, Kauffman CA, Andes D et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503–535PubMed

95.

Spanakis EK, Aperis G, Mylonakis E (2006) New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 43:1060–1068PubMed

96.

Kwon DS, Mylonakis E (2007) Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother 8:1167–1178PubMed

97.

Langner S, Staber PB, Neumeister P (2008) Posaconazole in the management of refractory invasive fungal infections. Ther Clin Risk Manag 4:747–758PubMed

98.

Charlier C, Hart E, Lefort A et al (2006) Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 57:384–410PubMed

99.

Guinea J, Bouza E (2008) Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol 3:603–615PubMed

100.

Guinea J, Pelaez T, Recio S et al (2008) In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 52:1396–1400PubMed

101.

Shan YS, Sy ED, Wang ST et al (2006) Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery. World J Surg 30:119–126. doi:10.1007/s00268-005-7807-z PubMed

102.

Bohnen JM (1998) Antibiotic therapy for abdominal infection. World J Surg 22:152–157. doi:10.1007/s002689900363 PubMed

103.

Kourkoumpetis TK, Velmahos GC, Ziakas PD et al (2011) The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients. Mycopathologia 171:85–91PubMed

104.

O’Connell K, Lyons M, Hanahoe B et al (2011) Antifungal susceptibility testing and candidaemia at a tertiary referral hospital. Ir Med J 104:55–56PubMed

105.

Slavin MA, Sorrell TC, Marriott D et al (2010) Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 65:1042–1051PubMed

106.

Tan TY, Tan AL, Tee NW et al (2008) A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. Ann Acad Med Singapore 37:835–840PubMed

107.

Solomkin JS, Mazuski JE, Bradley JS et al (2010) Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50:133–164PubMed

108.

Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640–3645PubMed

109.

Solomkin JS (2010) Evaluating evidence and grading recommendations: the SIS/IDSA guidelines for the treatment of complicated intra-abdominal infections. Surg Infect (Larchmt) 11:269–274

110.

Fabris A, Pellanda MV, Gardin C et al (1993) Pharmacokinetics of antifungal agents. Perit Dial Int 13(Suppl 2):S380–S382PubMed

111.

Piraino B, Bailie GR, Bernardini J et al (2005) Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 25:107–131PubMed

112.

Senn L, Eggimann P, Ksontini R et al (2009) Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med 35:903–908PubMed

113.

Playford EG, Webster AC, Sorrell TC et al (2006) Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 57:628–638PubMed

114.

Shorr AF, Chung K, Jackson WL et al (2005) Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 33:1928–1935; quiz 1936PubMed

115.

Cruciani M, de Lalla F, Mengoli C (2005) Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 31:1479–1487PubMed

116.

Cruciani M, Mengoli C, Malena M et al (2006) Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 12:850–858PubMed

117.

Leon C, Ruiz-Santana S, Saavedra P et al (2006) A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730–737PubMed

118.

van der Velden WJ, Plantinga TS, Donnelly JP et al (2010) Host-microbe interactions in stem cell transplantation: recognizing Candida in infection and inflammation. Virulence 1:180–184PubMed

119.

Bond S, Stewart DL, Bendon RW (2000) Invasive Candida enteritis of the newborn. J Pediatr Surg 35:1496–1498PubMed

120.

Rodrigues RJ, Wolff WI (1974) Fungal septicemia in surgical patients. Ann Surg 180:741–746PubMed

121.

Eggimann P, Francioli P, Bille J et al (1999) Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 27:1066–1072PubMed

Titel: Candida Peritonitis: An Update on the Latest Research and Treatments
verfasst von: Herman Anthony Carneiro
Anastasios Mavrakis
Eleftherios Mylonakis
Publikationsdatum: 01.12.2011
Verlag: Springer-Verlag
Erschienen in: World Journal of Surgery / Ausgabe 12/2011
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-011-1305-2

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2011

Single-Photon-Emission Computed Tomography (SPECT) with 99Technetium Sestamibi in the Diagnosis of Small Breast Cancer and Axillary Node Involvement

Elective Global Surgery Rotations for Residents: A Call for Cooperation and Consortium

The Impact of Heavy Smoking on Anastomotic Leakage and Stricture After Low Anterior Resection in Rectal Cancer Patients

Risk Factors for Stroke During Surgery for Carotid Body Tumors: Reply

Multivisceral Resections in Pancreatic Cancer: Identification of Risk Factors

Surgery, Public Health, and Pakistan

Update Chirurgie